Abstract
Previous reports of POF demonstrated promising efficacy for patients with AGC (ASCO-GI 2019). Apatinib, a small molecule tyrosine kinase inhibitor, can be safely administered up to 850 mg daily combined with POF in AGC (ESMO 2019). The PD-1 inhibitor nivolumab provided superior OS, along with PFS benefit, in combination with chemotherapy in UAGC in the CheckMate-649 study. Camrelizumab, in combination with apatinib, has been demonstrated clinical benefits in multiple advanced solid tumors. On the basis of these results, we conducted this trial to evaluate the safety and efficacy of first-line camrelizumab plus apatinib combined with POF in patients with UAGC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
